Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
February 05 2024 - 7:00AM
Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic
medicine company dedicated to pioneering treatments for genetically
defined cardiovascular diseases and APOE4-associated Alzheimer's
disease, today announced new executive appointments to lead the
evolution of the company’s pipeline into late-stage clinical
development.
“The accumulating talent bench at Lexeo has
overseen some of the most transformative clinical development
programs, drug approvals and product launches in rare disease and
precision cardiovascular medicine,” said R. Nolan Townsend, Chief
Executive Officer of Lexeo Therapeutics. “We look forward to
benefiting from this group’s thought leadership and operational
experience as we progress the Lexeo pipeline towards late-stage
studies.”
The appointments include:
- Sandi See Tai, MD, has been promoted to
Chief Development Officer. Prior to Lexeo, Dr. See
Tai was VP & Development Head for Rare Disease at Pfizer,
responsible for setting the Rare Disease internal portfolio
strategy and delivering its clinical development portfolio of
investigational products and in-line assets. She served as the
Medicine Team Lead for clinical programs across multiple
therapeutic areas including Rare Cardiovascular, Neurology, Renal
and Pulmonary disease areas. During her tenure, Dr. See Tai led the
late-stage clinical development program of tafamidis for ATTR
cardiomyopathy (ATTR-ACT), which achieved global regulatory
approvals, and the Phase 3 LMNA dilated cardiomyopathy clinical
program. In addition to late-stage clinical development, Dr. See
Tai was responsible for strategic clinical planning for early-stage
development candidates such as those for other genetic
cardiomyopathies and Duchenne Muscular Dystrophy. With almost 20
years of experience in the pharmaceutical industry, Dr. See Tai
held multiple roles of increased scope and responsibility across
Global Medical Affairs in Transplantation at Wyeth Pharmaceuticals
before moving into clinical development at Pfizer. Prior to joining
the pharmaceutical industry, Dr. See Tai was Assistant Professor of
Pediatrics at Drexel University College of Medicine and Attending
Physician in Pediatric Nephrology at St. Christopher’s Hospital for
Children, Philadelphia, where she also completed her General
Pediatrics residency and Pediatric Nephrology fellowship. She
received her MD from Tufts University School of Medicine,
Boston.
- Eric Adler, MD, has been appointed
Chief Medical Officer & Head of Research. As a
pioneer and thought leader in cardiovascular gene therapy, Dr.
Adler formerly served as Chief Scientific Officer at Lexeo since
joining in 2022. Prior to this role, Dr. Adler served as Professor
of Medicine, head of the Heart Failure Section, Director of the
Strauss Center for Cardiomyopathy, and the Czarina and Humberto S.
Lopez Chancellor’s Endowed Chair in Cardiology at the University of
California, San Diego (UCSD). Dr. Adler’s work has led to the
development of a novel cardiovascular gene therapy candidate
entering late-stage clinical development. His research is focused
on the study and treatment of cardiomyopathy, and he has published
over 100 papers in peer reviewed journals on the topic. Dr. Adler
is currently an associate editor of Circulation Hearth Failure and
has served on leadership, grant review, and guidelines committees
for the American Heart Association, the Heart Failure Society of
America, the International Society of Heart and Lung Transplant,
and the National Institute of Health. Dr. Adler earned his medical
degree from the Boston University School of Medicine.
- Rajiv Patni, MD, has been appointed
Senior Advisor to the Chief Executive Officer and
Board of Directors of Lexeo. Dr. Patni was formerly Chief Research
and Development Officer at Reata Pharmaceuticals (acquired by
Biogen for $7.3 billion), a commercial-stage biopharmaceutical
company that received approval for Skyclarys, the first
FDA-approved therapy for Friedreich’s ataxia. Prior to this role,
Dr. Patni served as Chief Medical Officer at several public,
small-cap, commercial-stage biopharmaceutical companies including
Portola (acquired by Alexion for $1.4 billion) and Global Blood
Therapeutics (acquired by Pfizer for $5.4 billion) and at those
companies, Dr. Patni oversaw the clinical studies leading to the
approvals of Andexxa and Oxbryta. Dr. Patni joined these companies
at inflection points in their research and development growth
trajectories and significantly supported their successful
acquisitions. Over his 24-year industry tenure in global product
development, Dr. Patni has contributed to the development of 21 new
chemical entities in several therapeutic areas including
cardiology, diabetology, hepatology, neurology, and benign
hematology. His experience in fostering successful teams from 35 to
250 colleagues contributed to the approval of 11 medicines from the
US FDA, EMA, and other regulatory agencies. The recent approvals
include medicines for several rare diseases such as pulmonary
arterial hypertension, advanced Parkinson’s disease, sickle cell
disease, and Friedrich’s ataxia. Dr. Patni received his MD from the
Mount Sinai School of Medicine in New York City as part of an
accelerated BS/MD Program. He completed his internal medicine
residency and adult cardiology fellowship at the Albert Einstein
College of Medicine, also in New York City, where he continued as
an attending physician-scientist before joining the
biopharmaceutical industry.
- Jenny R. Robertson has been appointed
Chief Business and Legal Officer. Ms. Robertson
formerly served as Chief Legal and Administrative Officer at Lexeo,
leading legal, human resources, information technology, information
security, and facilities strategies and activities. Prior to Lexeo,
Ms. Robertson served as Chief Counsel to Pfizer’s Oncology Business
Unit and held other senior legal roles including Chief Counsel for
Pfizer’s Rare Disease Business Unit, where she led the global legal
team for five years. Across positions at Pfizer, Ms. Robertson
counseled clients on a range of business and legal matters
including commercialization, disclosure, business development,
alliance management, clinical development, intellectual property
issues and litigation. Before joining Pfizer in 2010, Ms. Robertson
spent 10 years in private practice with a large international law
firm in New York and Washington, D.C., engaged in complex
commercial litigation with a healthcare focus. Ms. Robertson holds
a Bachelor of Arts Degree in Political Science from Southern
Illinois University and a J.D. from the Georgetown University Law
Center, where she co-founded and served as Editor-in-Chief of The
Georgetown Journal of Gender and the Law.
About Lexeo TherapeuticsLexeo Therapeutics is a
New York City-based, clinical stage genetic medicine company
dedicated to transforming healthcare by applying pioneering science
to fundamentally change how genetically defined cardiovascular
diseases and APOE4-associated Alzheimer’s disease are treated.
Using a stepwise development approach, Lexeo is leveraging early
proof-of-concept functional and biomarker data to advance a
pipeline of cardiovascular and APOE4-associated Alzheimer’s disease
programs.
Media Response:Janine Bogris(201)
245-6838janine.bogris@canalecomm.com
Investor Response:Laurence Watts(619)
916-7620laurence@gilmartinir.com
Lexeo Therapeutics (NASDAQ:LXEO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexeo Therapeutics (NASDAQ:LXEO)
Historical Stock Chart
From Jul 2023 to Jul 2024